Table 2.
Summary of different protocols for T cell priming assays
| T cells | APC | Stimulation | Readout | Reference |
|---|---|---|---|---|
| Priming of naive T cells | ||||
| Total peripheral blood T cells (CD45RA+ and CD45RO+) | Freshly prepared LC-enriched epithelial cells, cultured LC | TNP- or FITC-modified LC-enriched epithelial cells, cultured LC | Proliferation | [42] |
| Cultured LC | TNBS- or FITC-modified cultured LC; addition of PPD, BB, citronellal, hydroxycitronellal, coumarin, dihydrocoumarin | Proliferation | [43] | |
| Purified CD3+ T cells | Fresh adherent PBMC, GM-CSF-treated cultured PBMC, LC | DNCB-modified fresh PBMC, cultured PBMC, LC | Proliferation, IFN-γ ELISA | [44] |
| Total naive peripheral or cord blood T cells (CD45RA+ or CD45RO+) | CD34+ cord blood-derived DC, CD1a-enriched DC | TNBS-, FITC-modified DC | Proliferation | [45] |
| Cord blood T cells | CD34+ cord blood-derived LC-like DC | TNBS-, FITC-modified DC; addition of PPD, BB, citronellal, coumarin; addition of IL-1β | Proliferation | [46] |
| CD45RA+ and CD45RO+ T cells | CD1a+ DC, monocyte-derived DC | Addition of nickel, methacrylates (HEMA etc.); addition of IL-12 and/or IL-4 | Proliferation; IFN-γ, IL-5 ELISA | [47] |
| CD45RA+ T cells | moDC matured with TNF-α | TNBS-, FITC-modified moDC | Proliferation | [48] |
| PBMC | PBMC | Addition of PPD, BB, K2Cr207, CrCl3, CoCl, MCI, NiSO4, fragrance mix; addition of IL-7, IL-12 | Proliferation; IFN-γ, IL-5 ELISA | [49] |
| CD25-depleted lymphocytes | moDC | Addition of TNBS, FITC, hexylcinnamic aldehyde | Proliferation; IFN-γ ELISA | [50] |
| CD25−CD45RA+ T cells | Immature moDC, maturation with lipopolysaccharide or TNF-α | TNBS-, FITC-modified DC; addition of DNCB, 2,4-dinitrophenyl-modified HSA; addition of IL-2, IL-7, IL-15 | Proliferation; IFN-γ ICS, IFN-γ secretion assay | [51] |
| Recall responses with HSA-coupled chemicals (PenG, Ni, PPD) | ||||
| PBMC | PBMC, B-lymphoblastoid cell line cells | Penicillin G, penicillin G-coupled HSA | Proliferation (LTT) | [52] |
| T cell clones from Ni-allergic patients | moDC, Epstein-Barr virus B cells | NiSO4, HSA-Ni | Proliferation | [53] |
| Lymphocytes from allergic patients, T cell lines, clones | PBMC, Epstein-Barr virus B cells | Addition of PPD; PPD-modified HSA | Proliferation | [54] |